Pharmaceutical

Model N Responds to Mounting Regulatory Pharma Pressures with Innovations that Ensure Compliance and Optimize Revenue

340B, Inflation Reduction Act, and global pricing innovations help leading life sciences companies manage regulatory, compliance, and discounting challengesSAN MATEO,…

1 year ago

OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders

Co-led by Longitude Capital and Enavate Sciences, with Significant Participation by Existing Investors Samsara BioCapital and NuevaBioMENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio,…

1 year ago

Glaukos Announces Participation in Stifel Healthcare Conference

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the…

1 year ago

Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year

CAMBRIDGE, MA / ACCESSWIRE / November 7, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one…

1 year ago

PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal

TARRYTOWN, NY / ACCESSWIRE / November 7, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for…

1 year ago

PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa

Shipment marks the first batch of Psychedelic molecules explicitly for the Authorized Prescriber SchemeVANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE…

1 year ago

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and…

1 year ago

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025…

1 year ago

LAPIX Therapeutics Inc. Announces First Subjects Dosed in its First-in-Human Clinical Study of its Treg-expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis and other Autoimmune Conditions

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a biopharmaceutical company focused on developing novel, orally bioavailable…

1 year ago